Three minutes after placement into the chamber, rats were given three presentations of the tone conditioned stimulus (CS
dual GLP-1/GIP RA often categorized with GLP-1 meds), liraglutide (Victoza, Saxenda), dulaglutide (Trulicity), exenatide (Bydureon, Byetta), and others like lixisenatide (Adlyxin) and oral semaglutide formulations
Patients report a range of sleep-related changes during GLP1 treatment: Improvements many patients notice: Less snoring, often reported by partners before patients notice it themselves Fewer nighttime awakenings Feeling more rested in the morning Reduced daytime sleepiness Disruptions some patients experience: Insomnia or difficulty falling asleep, particularly during dose escalation Vivid dreams or nightmares, which some attribute to changes in sleep architecture as apnea resolves Nighttime nausea or acid reflux that disrupts sleep, especially if eating too close to bedtime Changes in sleep schedule as energy levels shift with weight loss These disruptions are generally temporary and often resolve within a few weeks at a stable dose
This review aimed to explore the molecular mechanisms underlying APAP-induced liver injury, particularly inflammasome activation, and evaluate the current and emerging therapeutic strategies
